Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Becton, Dickinson and Company NYSE: BDX. In a filing disclosed on April 28th, the Representative disclosed that they had sold between $1,001 and $15,000 in Becton, Dickinson and Company stock on April 8th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of DexCom NASDAQ: DXCM on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Invesco NYSE: IVZ on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Generac NYSE: GNRC on 4/8/2025.
- Sold $15,001 - $50,000 in shares of Occidental Petroleum NYSE: OXY on 4/8/2025.
- Sold $15,001 - $50,000 in shares of Pfizer NYSE: PFE on 4/8/2025.
- Sold $1,001 - $15,000 in shares of QUALCOMM NASDAQ: QCOM on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Best Buy NYSE: BBY on 4/8/2025.
- Sold $1,001 - $15,000 in shares of EOG Resources NYSE: EOG on 4/8/2025.
- Sold $1,001 - $15,000 in shares of CSX NASDAQ: CSX on 4/8/2025.
- Sold $1,001 - $15,000 in shares of Valero Energy NYSE: VLO on 4/8/2025.
Becton, Dickinson and Company Stock Performance
NYSE BDX opened at $206.30 on Wednesday. Becton, Dickinson and Company has a 1-year low of $193.03 and a 1-year high of $251.99. The company has a market capitalization of $59.24 billion, a P/E ratio of 34.27, a PEG ratio of 1.63 and a beta of 0.35. The business has a 50 day moving average price of $217.62 and a 200 day moving average price of $226.83. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts' consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.
Becton, Dickinson and Company declared that its board has authorized a stock repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to purchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's board of directors believes its stock is undervalued.
Becton, Dickinson and Company Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Monday, June 30th. Stockholders of record on Monday, June 9th will be paid a dividend of $1.04 per share. This represents a $4.16 dividend on an annualized basis and a dividend yield of 2.02%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 69.10%.
Institutional Trading of Becton, Dickinson and Company
A number of hedge funds have recently made changes to their positions in the stock. Bank of Jackson Hole Trust bought a new position in Becton, Dickinson and Company during the 4th quarter worth approximately $25,000. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at about $27,000. Sierra Ocean LLC bought a new position in Becton, Dickinson and Company in the 4th quarter worth approximately $29,000. REAP Financial Group LLC grew its stake in shares of Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after purchasing an additional 55 shares in the last quarter. Finally, Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Institutional investors and hedge funds own 86.97% of the company's stock.
Insider Activity
In related news, Director Bertram L. Scott sold 700 shares of the stock in a transaction on Wednesday, February 12th. The stock was sold at an average price of $227.99, for a total value of $159,593.00. Following the completion of the transaction, the director now owns 36,033 shares in the company, valued at $8,215,163.67. This trade represents a 1.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson acquired 1,500 shares of the business's stock in a transaction on Monday, February 10th. The shares were bought at an average price of $233.62 per share, for a total transaction of $350,430.00. Following the acquisition, the director now owns 8,015 shares in the company, valued at approximately $1,872,464.30. This trade represents a 23.02 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 3,578 shares of company stock worth $795,986. 0.36% of the stock is owned by company insiders.
Analyst Ratings Changes
Several brokerages recently issued reports on BDX. Barclays reduced their price objective on shares of Becton, Dickinson and Company from $279.00 to $261.00 and set an "overweight" rating on the stock in a research note on Monday, April 7th. Piper Sandler decreased their target price on Becton, Dickinson and Company from $280.00 to $260.00 and set an "overweight" rating for the company in a report on Wednesday, April 23rd. Finally, StockNews.com raised Becton, Dickinson and Company from a "hold" rating to a "buy" rating in a research report on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $272.86.
Read Our Latest Stock Analysis on BDX
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
Becton, Dickinson and Company Company Profile
(
Get Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
